Please assess the completion status of the following clinical trial:

Trial Title: Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients ≥18 years of age with 24-96 hours of urinary symptoms attributable to a urinary tract infection (UTI)~2. Two of the following signs and symptoms of uUTI: urinary frequency, urinary urgency, pain or burning micturition, suprapubic pain~3. A mid-stream urine specimen with:~   1. a dipstick analysis positive for nitrite AND~  2. evidence of pyuria as defined by either:~   i. a dipstick analysis positive for leukocyte esterase ii. at least 10 white blood cells per cubic millimeter on microscopic analysis of unspun urine iii. White blood cell count ≥10 cells/high-powered field in the sediment of a spun urine~4. Has given written informed consent to participate in the study.~Exclusion Criteria:~1. Presence of signs and symptoms suggestive of acute pyelonephritis: fever (temperature \> 38°Celsius), chills, costovertebral angle tenderness, flank pain, nausea, and/or vomiting~2. Receipt of antibacterial drug therapy potentially effective as treatment of uUTI within the prior 7 days~3. Concurrent use of non-study treatments that would have a potential effect on outcome evaluations in patients with uUTI~4. Patients with ileal loops or urinary stoma~5. Patients with an indwelling urinary catheter in the previous 30 days~6. Patients with paraplegia~7. Patients who are likely to receive ongoing antibacterial drug prophylaxis after treatment of uUTI (e.g., patients with vesico-ureteral reflux)~8. Any history of trauma to the pelvis or urinary tract~9. Patient's urine culture, if available at study entry, identify more than 2 microorganisms regardless of colony count or patient has a confirmed fungal UTI~10. Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant~11. Known history of creatinine clearance \<50 mL/min~12. Patients known to have liver disease~13. Patients who are pregnant, or females of child-bearing age unable to take adequate contraceptive precautions~14. Patients with uncontrolled diabetes mellitus~15. Patients with history of blood dyscrasias~16. Patients with history of uric acid kidney stones~17. Patients with acute gouty attack~18. Patients on chronic methotrexate therapy~19. Patient known to be immunocompromised~20. Patients with a known history of myasthenia gravis~21. Patients who require concomitant administration of tizanidine or valproic acid~22. Patients with a history of allergy or hypersensitivity to carbapenems, beta-lactams, quinolones or probenecid~23. Patient is considered unlikely to survive the 4-week study period or has a rapidly progressive or terminal illness including septic shock which is associated with a high risk of mortality~24. History of seizures~25. Use of any other investigational drug in the 30 days prior to the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sulopenem-etzadroxil/probenecid (Type: EXPERIMENTAL): Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
- Ciprofloxacin (Type: ACTIVE_COMPARATOR): Ciprofloxacin 250 mg PO administered twice daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).